{"id":"NCT04767373","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)","officialTitle":"A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2021-04-07","primaryCompletion":"2024-07-09","completion":"2024-07-09","firstPosted":"2021-02-23","resultsPosted":"2025-02-04","lastUpdate":"2025-05-06"},"enrollment":3632,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Respiratory Syncytial Virus Infection"],"interventions":[{"type":"BIOLOGICAL","name":"Clesrovimab","otherNames":["MK-1654"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Clesrovimab 105 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objectives of this phase 2b/3 double-blind, randomized, placebo-controlled study are to evaluate the efficacy and safety of clesrovimab in healthy pre-term and full-term infants. It is hypothesized that clesrovimab will reduce the incidence of respiratory syncytial virus (RSV)-associated medically attended lower respiratory infection (MALRI) from Days 1 through 150 postdose compared to placebo.","primaryOutcome":{"measure":"RSV Season 1: Number of Participants With Respiratory Syncytial Virus (RSV)-Associated Medically Attended Lower Respiratory Infection (MALRI)","timeFrame":"From Day 1 (postdose) to Day 150","effectByArm":[{"arm":"RSV Season 1: Clesrovimab 105 mg","deltaMin":60,"sd":null},{"arm":"RSV Season 1: Placebo","deltaMin":74,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":217,"countries":["United States","Argentina","Belgium","Canada","Chile","China","Colombia","Denmark","Finland","France","Israel","Italy","Japan","Malaysia","Mexico","Peru","Philippines","Poland","Romania","South Africa","South Korea","Thailand","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["34774184"],"seeAlso":["https://www.merckclinicaltrials.com/","https://msd.trialsummaries.com/Study/StudyDetails?id=26484&tenant=MT_MSD_9011"]},"adverseEventsSummary":{"seriousAny":{"events":282,"n":2409},"commonTop":["Irritability","Upper respiratory tract infection","Somnolence","Body temperature increased","Nasal congestion"]}}